China Renaissance Healthcare & Life Sciences Weekly Report Vol.416 Highlights Record-Breaking Financings and Regulatory Milestones

Jul 06, 2026 09:35 CST Updated 09:35

iRegene Therapeutics

Cell Therapy Product Developer

“China Renaissance Healthcare and Life Sciences Industry Weekly Report” is regularly published, focusing on interpreting weekly data from a capital perspective and providing the latest industry insights.

Healthcare and life sciences have been key sectors of focus and deep cultivation for China Renaissance Capital over the years, with the firm having served as financial advisor to nearly 200 financing and M&A transactions.

Continuous innovation in the healthcare and life sciences sector has made it one of the most dynamic industries; China Renaissance has consistently supported and accompanied the growth of startups in this field, committed to bringing rational and professional insights to the industry.

Author | China Renaissance Healthcare and Life Sciences Team

Follow the China Renaissance WeChat official account (ID: iChinaRenaissance), and click “Renaissance Insights” - “Industry Observations” - “Life Sciences” in the backend to access more information on the healthcare and life sciences industries.

Gestalt Technology Completes RMB 420 Million Angel+ Round of Financing, Shanghai Headquarters Officially Opens

On July 3, 2026, Gestala announced the completion of its RMB 420 million Angel+ financing round. The round was led by Huaying Capital, with participation from C Capital, Sequoia China, Lens Technology, CEC Health Fund, Sinovation Ventures, Lingang Sci-Tech Innovation Investment, Fudan Furong Capital, Guotai Venture Capital, and other leading domestic and international investment institutions. Existing shareholders, including Daotong Investment, Yunshi Capital, Qingsong Capital, and Gobi Partners, continued to oversubscribe significantly. China Renaissance served as the exclusive financial advisor.

Industry Perspective:

The deep integration of brain-computer interfaces (BCI) and AI stands at the crossroads of technology and humanity’s future. Gestalt Technology has visionaryly constructed a cutting-edge business matrix combining BCI with AI for Science (AI4S). The company has not only achieved breakthroughs in hardware-level neural signal modulation and acquisition but also, at the foundational level of software and science, is leveraging a top-tier “Brain Bank” currently under full-scale construction in Shanghai to create an unprecedented Brain Foundation Model. This unique synergy, perfectly merging biological intelligence with computational science, constitutes the competitive moat that enables Gestalt to consistently lead the industry.

Source:VBData

State-owned capital from Chengdu and Wuxi invests in an AI drug discovery company

On July 2, iRegene Therapeutics announced the completion of its C+ round financing amounting to RMB 260 million. The round was led by Chengdu Science and Technology Innovation Investment, with participation from institutions such as CSC Financial Capital. Existing shareholders, including Yuanxi Haihe, made additional investments. This marks the second financing round completed within one month. Earlier in early June 2026, iRegene Therapeutics closed a RMB 210 million financing round, jointly led by Photosynthesis Ventures and Xingze Capital.

Industry Perspective:

iRegene Therapeutics, established in 2017, focuses on small-molecule chemical transcriptional regulation of induced pluripotent stem cells (iPSCs) and has built an “AI + chemical induction” platform for cell therapy drug development, with a portfolio of multiple product candidates. Its lead asset, NouvNeu001 injection, is the world’s first iPSC-derived universal dopaminergic precursor cell therapy for Parkinson’s disease to enter clinical development; it has received multiple FDA designations and has completed partial dosing in Phase II trials in both China and the United States. NouvNeu004 has entered synchronized clinical development in China and the United States, and the company also has a presence in ophthalmology, evolving into a platform-type biotech.

Source:Zhiyao Bureau

Yanming Bio Announces Completion of Pre-B Financing Round Worth Hundreds of Millions of RMB

On July 3, 2026, Beijing Yanming Biotechnology Co., Ltd. announced the completion of its Pre-B financing round, raising hundreds of millions of RMB. The round was led by Shanghai State-owned Capital Venture Guide Fund, with participation from Beijing Zhongguancun Science City Fund and Minjin Investment Company. Existing investors, including China Reform Holdings Corporation Fund, Beijing Medicine and Health Industry Fund, Qinglan Capital, FreeS Fund, Qisheng Capital, Changfa Development Group, and Zhongfa Lingchuang, continued to increase their investments.

Industry Perspective:

The funds raised in this financing round will be used to support the development and project implementation of the pyroptosis bio-regulation novel drug R&D technology platform at the Shanghai subsidiary, advance the clinical development of multiple projects under the Beijing small-molecule immunomodulator drug R&D platform, accelerate the progress of several preclinical research projects, and further expand the R&D pipeline. By leveraging the resource advantages of both Beijing and Shanghai, this initiative aims to contribute to the sustained development of China’s pharmaceutical and healthcare industry.

Source: Yanming Biologics

Rushen Robotics Completes CNY 100 Million Pre-A Funding Round, Building an Embodied AI System Capability Platform for Real-World Elderly Care Scenarios

Recently, Shanghai Rushen Robotics Technology Co., Ltd. announced the completion of its hundred-million-yuan Pre-A financing round in late April. This round was jointly invested by Qingsong Capital, a well-known healthcare fund; Runze Technology, a leading listed company in computing power; and Pinghu Zexin. The funds will be used to accelerate the deployment and implementation of embodied AI in elderly care institutions and home settings.

Industry Perspective:

In this round of financing, Qingsong Capital and Runze Technology provided synergistic support from the perspectives of healthcare scenario capabilities and AI infrastructure computing power, respectively, jointly forming a key industrial support structure for Rushen Robot’s continuous operation, data generation, and model iteration in real-world elderly care scenarios.

Source:VBData

Hanyue Advanced Materials Completes Tens of Millions in Pre-A Financing, Deepening Its Focus on the Disposable Solutions Sector

Recently, Hanyue Advanced Materials (including its subsidiary, Hanyue Biomaterials Shanghai Co., Ltd.) officially announced the completion of a Pre-A financing round amounting to tens of millions of RMB, with Longpan Investment as the sole investor.

Industry Perspective:

As a high-quality enterprise focusing on high-end new materials and core supporting areas for biopharmaceuticals, Hanyue Advanced Materials and its group company have deeply cultivated the industry for many years. They have precisely laid out their strategy in the highly promising single-use solutions track for biopharmaceuticals. Relying on independently controllable material research and development technology, stable and compliant product quality, and a one-stop supporting service system, they have built profound technical and market barriers in niche fields.

Source:VCBeat

Soft Sense Completes Angel Round to Accelerate Development of Fully In-House Developed, Reusable Medical-Grade Flexible Sensing Platform

Soft Sense (Xiamen Guanjun Zhichuang Technology Co., Ltd.), a medical-grade flexible sensing platform enterprise, has recently completed an angel financing round worth millions of US dollars. Positioned as a fully self-developed medical-grade flexible sensing platform, Soft Sense is dedicated to creating smart clothing capable of long-term, continuous monitoring of human physiological signals. Centered on its proprietary machine-washable flexible sensing technology, the company has built a medical-grade wearable platform encompassing hardware, algorithms, and data services. It has currently established a presence in four key application areas: cardiovascular monitoring, elderly care, neuromuscular rehabilitation, and sports health.

Industry Perspective:

This round of financing will accelerate the commercialization of core technologies, rapidly validate the commercial viability of the medical-grade washable wearable platform, and establish a proprietary medical data ecosystem. Dr. Zhou Guanqian, Founder and CTO of Soft Sense, stated, “Over the next two years, we aim to achieve standardization and large-scale production of smart clothing, continuously bringing high-end medical-grade technology down to the consumer market—enabling early detection of critical health risks through uninterrupted continuous monitoring, and truly integrating professional medical care into everyday life.”

Source:VBData

“Announcement on Including 16 Substances, Such as Difluoroetomidate, in the ‘Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances’” Effective from July 1

In accordance with the relevant provisions of the Regulations on the Control of Narcotic Drugs and Psychotropic Substances and the Measures for the Control of Non-Medicinal Narcotic Drugs and Psychotropic Substances, the Ministry of Public Security, the National Health Commission, and the National Medical Products Administration have decided to include 16 substances, including difluoroetomidate, in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances. This announcement shall come into effect on July 1, 2026. Any substance included in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances is legally defined as a drug, and its production, trade, transportation, use, storage, and import/export are prohibited for any entity or individual.

• Yangtze River Pharmaceutical Group's Innovative Andrology Drug, Tonadafil Hydrochloride Tablets (Taituotuo^®) Full market launch

• Yizekang: The World’s First Bispecific Antibody-Drug Conjugate (ADC)^®JD DTP Pharmacy National Launch

• Viridian Therapeutics’ Antibody Therapy for Thyroid Eye Disease Approved by the FDA

• Breakthrough Small-Molecule Phase 3 Results Published in NEJM, Marketing Authorization Application Imminent

• Breaking! U.S. FDA Approves Allogeneic Cell Therapy for Market Launch

• Multiple Medical Device Products Approved for Market Launch

Yangtze River Pharmaceutical Group’s Innovative Andrology Drug, Tonadafil Hydrochloride Tablets (Taituotuo^®) Full Market Launch

Recently, Yangtze River Pharmaceutical Group announced that its innovative drug for men’s health, Tonadafil Hydrochloride Tablets (Tai Tuotuo^®) Full market launch. Tonadafil Hydrochloride Tablets are a Class 1 innovative drug, independently developed by Yangtze River Pharmaceutical Group, acting as a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED). Through optimized molecular structure design, it exhibits enhanced inhibitory activity and selectivity against the target. While ensuring favorable clinical efficacy, it is minimally affected by food intake and alcohol consumption, offering greater flexibility in administration. Phase III clinical studies demonstrated that Tonadafil Hydrochloride Tablets improve erectile function in patients with ED. The relevant research findings were presented as an oral report at the World Meeting on Sexual Medicine (WMSM 2026) in 2026.

Source: VBData

Yizekang: The World’s First Bispecific Antibody-Drug Conjugate (ADC)^®JD.com DTP Pharmacy Nationwide Launch

Recently, the world’s first approved EGFR×HER3 bispecific antibody-drug conjugate (ADC), lunkangyilongtuomab (brand name: Yizekang^®) officially launched nationwide for the first time on JD DTP Pharmacy. This not only marks the fastest market rollout since the innovative drug received approval from the National Medical Products Administration (NMPA) this June, but also signifies that patients in China with recurrent/metastatic nasopharyngeal carcinoma will be among the first to benefit from the cutting-edge global therapeutic approach of “bispecific antibody + ADC.” In this process, JD Health has played a pivotal role in bridging the “last mile” to clinical accessibility.

Source: VBData

Viridian Therapeutics’ Antibody Therapy for Thyroid Eye Disease Approved by FDA

Viridian Therapeutics recently announced that the U.S. FDA has approved Lumvoa (veligrotug) for the treatment of thyroid eye disease (TED). TED is a rare, disabling autoimmune disease characterized by inflammation and tissue remodeling in the periorbital and retrobulbar tissues, which can lead to proptosis, diplopia, pain, and visual impairment.

Source:WuXi AppTec

Breakthrough Small Molecule Phase 3 Results Published in NEJM, Marketing Authorization Application Imminent

BridgeBio Pharma recently announced that the positive results from the PROPEL 3 global pivotal Phase 3 study have been published in The New England Journal of Medicine (NEJM). PROPEL 3 evaluated the efficacy and safety of oral infigratinib in pediatric patients with achondroplasia.

Source:WuXi AppTec

Breaking! U.S. FDA Approves Allogeneic Cell Therapy for Market Launch

The U.S. FDA Announces Approval of Orca Bio’s Tregzi to Improve Chronic Graft-versus-Host Disease (GVHD)-Free Survival in Adult Patients with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)The U.S. Food and Drug Administration (FDA) announced today the approval of Tregzi, developed by Orca Bio, for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). For certain adult patients with high-risk hematologic malignancies, this therapy represents a novel approach to allo-HSCT. It addresses a significant unmet need in the transplant field, where treating cancer is often only part of the challenge; avoiding chronic GVHD is equally critical for long-term outcomes.

Source: WuXi AppTec

Multiple Medical Device Products Approved for Market Launch

Tripled-Frequency Nd:YAG Laser Ablation Device Approved for Market Launch

On June 26, 2026, the National Medical Products Administration (NMPA) approved the registration application for the triple-frequency Nd:YAG laser ablation device submitted by Shenzhen Zhongke Rongguang Medical Technology Co., Ltd. The product consists of a main unit, a foot switch, and laser protective eyewear, and is used in conjunction with disposable laser fiber optic catheters for pre-treatment in the recanalization of atherosclerotic stenosis and occlusive lesions of the lower extremities. Utilizing triple-frequency solid-state laser technology, the device emits laser light at a wavelength of 355 nm and transmits laser energy via the catheter to the lesion site within the human body, thereby facilitating the recanalization of occlusive lesions and improving debulking efficiency. This product represents a domestic first-in-class innovation in China.

Source:VBData

Intracranial Aneurysm Embolization System Approved for Market Launch

On June 29, 2026, the National Medical Products Administration approved the innovative product registration application for the “Intrasaccular Embolization System for Aneurysms” submitted by Beijing Taijie Weiye Technology Co., Ltd. The product consists of an implantable component, a delivery system, and an introducer sheath. It is indicated for endovascular treatment of adult patients with unruptured, small-to-medium-sized, wide-necked saccular intracranial bifurcation aneurysms measuring 3 mm to 15 mm in diameter, with a neck width ≥4 mm or a neck ratio >1 and <2. Featuring a two-dimensional disc-shaped structure and a concave bottom design, the implantable component resides entirely within the aneurysm sac without covering the parent artery. Consequently, permanent dual antiplatelet therapy is generally not required post-procedure, which is expected to reduce the associated risk of bleeding.

Source:VCBeat

Implantable Cardiac Event Monitor Approved for Market Launch

On July 1, 2026, the National Medical Products Administration (NMPA) approved the registration application for the Implantable Cardiac Monitor (ICM) submitted by Suzhou Wushuang Medical Equipment Co., Ltd. The product consists of an Implantable Cardiac Monitor (ICM) and a patient activator. It is designed to record subcutaneous electrocardiograms and is indicated for patients who are at increased risk of arrhythmia or have been diagnosed with arrhythmia, particularly those experiencing clinical symptoms or a history of transient symptoms. As the first domestically developed Implantable Cardiac Monitor (ICM), this product fills a gap in China’s ICM field.

Source: VBData

Intracranial Stent Approved for Market Launch

On July 2, 2026, the National Medical Products Administration approved the innovative product registration application for the “Intracranial Stent” submitted by MicroPort NeuroTech (Shanghai) Co., Ltd. The product consists of a stent and a delivery system, and is intended to be used in conjunction with embolization devices for the treatment of wide-necked saccular aneurysms in the anterior circulation of the brain. The stent features a closed-cell helical wire interlacing design, a closed-loop structure, and full radiopacity, which are expected to provide excellent flexibility and wall apposition, allow for recapture and repositioning, and ensure accurate placement.

Source:VBData

STARMED Receives FDA 510(k) Clearance for the Indication of Ablation of Benign Thyroid Nodules

STARMED, a medical device company specializing in minimally invasive treatment technologies, has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for specific thyroid indications (K252833), effective May 26, 2026. This clearance permits the use of its system for ultrasound-guided percutaneous ablation of cytologically confirmed benign thyroid nodules in adult patients, making STARMED the first and only company globally to receive FDA clearance for thyroid nodule ablation. Henry Shin, CEO of STARMED, emphasized the significance of this milestone, noting that it culminates over two decades of technological development and close collaboration with physicians. Unlike general soft-tissue ablation indications, this clearance explicitly specifies thyroid nodules, ultrasound guidance, a percutaneous approach, adult patients, and defined clinical eligibility criteria. The cleared STAR radiofrequency electrode is designed to enhance the precision of ablation therapy for eligible benign thyroid nodules.

Source:VBData

FDA-Approved Tongue Neuromodulation System for Post-Stroke Gait Rehabilitation

Bioness Medical’s PoNS (Portable Neuromodulation Stimulator) System has received U.S. Food and Drug Administration (FDA) 510(k) clearance, becoming the first non-invasive, tongue-applied neuromodulation device for treating dynamic gait deficits resulting from chronic stroke symptoms. This approval expands treatment accessibility for more than seven million Americans with stroke-related gait disabilities and extends the indicated use of PoNS from its previously cleared indication for multiple sclerosis to include stroke. The device delivers mild neuromodulatory stimulation via an oral appliance placed on the tongue, activating branches of the trigeminal and facial cranial nerves to promote neuroplasticity and compensate for damaged corticospinal pathways. Designed for home use in conjunction with a supervised physical rehabilitation program, the device is intended for patients aged 22 years and older with chronic stroke, with the aim of improving walking function.

Source:VBData

• Bispecific antibody meets primary endpoint in Phase 3 clinical trial for the treatment of diffuse large B-cell lymphoma

• Submission of New Drug Application to the U.S. FDA for Innovative Small Molecule Therapy

• Sanofi’s Pompe Disease Therapy Meets Primary Endpoint in Phase 3 Clinical Trial

• Roche’s next-generation KRAS G12C inhibitor meets primary endpoint in Phase 3 clinical trial

• Revolution Medicines Announces Latest Clinical Results for RAS G12D Inhibitor

• Vertex Gene-Editing Cell Therapy Receives U.S. FDA Approval for Expanded Indications

Bispecific Antibody Meets Primary Endpoint in Phase 3 Trial for Diffuse Large B-Cell Lymphoma

AbbVie and Genmab recently announced the top-line results from the Phase 3 EPCORE DLBCL-4 clinical trial. The study evaluated the efficacy of epcoritamab, a T-cell-engaging bispecific antibody, in combination with lenalidomide, compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx), in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who had received at least one prior line of therapy.

Source:WuXi AppTec

Innovative Small-Molecule Therapy Submits New Drug Application to the U.S. FDA

Cogent Biosciences announced today that it has submitted a New Drug Application (NDA) to the U.S. FDA for bezuclastinib for the treatment of advanced systemic mastocytosis (AdvSM). This submission is based on positive clinical data from the pivotal APEX trial, which were recently presented at the 2026 European Hematology Association (EHA) Congress.

Source: WuXi AppTec

Sanofi’s Pompe Disease Therapy Meets Primary Endpoint in Phase 3 Clinical Trial

Sanofi Announces Positive Results from the Phase 3 Baby-COMET Clinical Trial of Nexviazyme (avalglucosidase alfa)Sanofi announced today that Nexviazyme (avalglucosidase alfa) achieved positive results in the Phase 3 Baby-COMET clinical trial. Nexviazyme met the primary endpoint, defined as the proportion of treatment-naïve pediatric subjects with infantile-onset Pompe disease (IOPD), aged 6 months or younger at baseline, who were alive and free from invasive ventilation after 52 weeks of treatment. Furthermore, the study met all secondary endpoints, including the proportion of subjects alive and free from invasive ventilation at 12 and 18 months of age, as well as numerical improvements in other disease progression markers at 52 weeks of treatment. These data will support a label expansion application in the United States, which is expected to be submitted in the second half of 2026.

Source:WuXi AppTec

Roche’s Next-Generation KRAS G12C Inhibitor Meets Primary Endpoint in Phase 3 Clinical Trial

Genentech, a member of the Roche Group, announced today that divarasib, an investigational next-generation KRAS G12C inhibitor, achieved positive results in the Phase 3 Krascendo 1 clinical trial for the treatment of previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The study met its primary and key secondary endpoints, with divarasib demonstrating clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to approved first-generation KRAS G12C inhibitors.

Source:WuXi AppTec

Revolution Medicines Announces Latest Clinical Results for RAS G12D Inhibitor

Revolution Medicines Announces Results from Two Phase 1/2 Clinical Trials Evaluating Zoldonrasib, an Oral RAS G12D-Selective Covalent Inhibitor, in Combination Regimens for Patients with RAS G12D-Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). The findings were presented today at the 2026 ESMO Gastrointestinal Cancers Congress.

Source:WuXi AppTec

Vertex’s Gene-Edited Cell Therapy Receives U.S. FDA Approval for Expanded Indications

Vertex Pharmaceuticals recently announced that the U.S. FDA has approved an expanded indication for Casgevy (exagamglogene autotemcel) for the treatment of patients aged 2 years and older with sickle cell disease (SCD) accompanied by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β-thalassemia (TDT).

Source: WuXi AppTec

• 1.34 Billion Yuan! An Autoimmune Monoclonal Antibody Nearing Market Launch Was Sold

• Acquisition of the company founded by George Church and his postdoctoral fellow

• Chinese founders established Thymmune, acquired by a multinational pharmaceutical company for $300 million

• Orthopedic giant Zimmer acquires postoperative cryoanalgesia device maker for $140 million

• Over €700 million: Ipsen Acquires Memo Therapeutics

• Another Molecular Diagnostics Company Acquired

RMB 1.34 Billion! A Near-Launch Autoimmune Monoclonal Antibody Sold

On the evening of July 1, Junshi Biosciences (688180.SH) announced that it had signed a License Agreement with Fosun Wanbang, a wholly-owned subsidiary of Fosun Pharma, on June 30. Under the agreement, Junshi Biosciences has divested the exclusive rights for the development, registration, manufacturing, and commercialization of its self-developed anti-IL-17A monoclonal antibody, ruokiqibart (JS005), in the Greater China region. The transaction consideration comprises a non-refundable upfront payment of RMB 215 million, tiered milestone payments totaling up to RMB 1.125 billion, and tiered sales royalties, bringing the total potential value to a maximum of RMB 1.34 billion.

Source: Arterial NetworkWeb

George Church and His Postdoctoral Fellow’s Company Acquired

On July 2, United Therapeutics announced the acquisition of Thymmune Therapeutics for $300 million. Thymmune is a preclinical-stage biotechnology company developing scalable regenerative thymic cell therapies for the treatment of post-transplant organ tolerance, immunodeficiency, and autoimmune diseases. Founded by Martine Rothblatt in 1996, United Therapeutics has transformed the treatment of rare diseases and currently has a market capitalization of $23.5 billion. Established in 2019 by renowned geneticist George Church and postdoctoral fellow Stan Wang, Thymmune completed a $7 million seed financing round in 2023 and received a $37 million grant from ARPA-H in September of the same year. Thymmune has translated Stan Wang’s postdoctoral research into a platform combining machine learning with induced stem cell engineering. The company possesses a proprietary process for converting human induced pluripotent stem cells (iPSCs) into thymic cells, and its lead candidate, THY-100, is currently undergoing preclinical development for congenital athymia.

Source:Medaverse

Chinese Founder Establishes Thymmune, Acquired by Multinational Pharmaceutical Company for $300 Million

On July 2, 2026, United Therapeutics announced the completion of its acquisition of Thymmune. Founded by Chinese entrepreneurs, Thymmune focuses on developing scalable regenerative thymic cell therapies for potential applications in inducing post-transplant organ immune tolerance, as well as treating immunodeficiency disorders and autoimmune diseases. The company possesses a proprietary platform that directs the differentiation of human induced pluripotent stem cells (iPSCs) into thymic epithelial cells, thereby restoring normal T-cell function in the body. Its lead candidate, THY-100, is currently in preclinical development for the treatment of congenital athymia; animal studies have confirmed its efficacy, paving the way for broader applications in thymic regenerative medicine. The Chairman of United Therapeutics stated that Thymmune’s technology platform aligns closely with the company’s core strategic vision and holds the promise of delivering transformative breakthroughs in human healthcare.

Source:PharmaCircle

Orthopedics Giant Zimmer Acquires Postoperative Cryoanalgesia Device for $140 Million

On June 30, 2026, orthopedic medical device giant Zimmer Biomet announced the acquisition of Pacira’s iovera° nerve treatment products and assets for up to $140 million, strengthening its position in perioperative pain management and knee replacement. The transaction adopts an “upfront payment + milestone payment” structure, with an upfront payment of $70 million and potential additional milestone payments of up to $70 million for Pacira. Upon completion of the transaction, Zimmer Biomet will fully acquire all rights to the development, manufacturing, and commercialization of iovera°. Originally developed by Myoscience, iovera° was acquired by Pacira in 2019. Furthermore, both parties will collaborate to advance the Phase III clinical trial of iovera° for upper limb spasticity, under which Pacira may receive additional compensation. The device uses nitrous oxide as a refrigerant to create reversible lesions through cryoneurolysis. It has received FDA approval for relieving pain associated with knee osteoarthritis, with effects lasting up to 90 days.

Source: MedTF

Over €700 Million: Ipsen Acquires Memo Therapeutics

On July 1, Ipsen and Memo Therapeutics entered into a definitive share purchase agreement, under which Ipsen acquired all issued and outstanding shares of Memo Therapeutics for over €700 million, with a focus on acquiring potravitug, a Phase II clinical-stage antibody targeting BK polyomavirus (BKPyV). BK polyomavirus-associated nephropathy is a serious complication in kidney transplant recipients. Potravitu received Fast Track designation from the U.S. FDA in May 2023 and orphan drug designation from the European Union in December 2025. The Head of R&D at Ipsen stated that this acquisition reinforces the company’s commitment to delivering transformative solutions for patients, as potravitug expands the rare disease pipeline and addresses BK virus-associated nephropathy in kidney transplant recipients. The Phase II SAFE Kidney II trial demonstrated that potravitug had superior efficacy compared to placebo, showing strong clinical value with sustained and significant antiviral activity, thereby reducing the incidence of BKPyVAN.

Source:Medaverse

Surpassing Invisalign, Smartee Orthodontics Races Toward IPO

On June 29, Smartee Dental submitted its IPO prospectus to the ChiNext board. As one of the representative enterprises in China’s clear aligner orthodontics sector, Smartee Dental was founded in 2004 and was among the early players to enter this market. Over more than two decades of development, the company has established a comprehensive product portfolio, including core categories such as the Classic Edition, Joy Edition, GS Series, and the Children & Adolescents Series, catering to diverse needs ranging from simple dental alignment to complex jaw position reconstruction. In 2023, 2024, and 2025, Smartee Dental reported operating revenues of RMB 648 million, RMB 786 million, and RMB 938 million, respectively.

Source: VCBeat

Statistical Period: June 29, 2026 - July 05, 2026

*Source: Internal compilation by China Renaissance

*Data Sources: Capital IQ, Prospectus, Research Reports, Company Annual Reports

Disclaimer: This document has been prepared by China Renaissance Holdings (together with its affiliates, collectively referred to as “China Renaissance”) solely for the recipient’s reference. It is not, and should not be construed as, a research report on any securities in any jurisdiction, nor does it constitute an invitation or assurance to buy, sell, or subscribe for securities or other financial instruments and products. The listed companies mentioned herein are provided for illustrative purposes only and do not represent any investment analysis or investment advice. Recipients should not rely solely on this document but should make their own investment decisions based on their independent judgment and seek professional advice before taking any investment actions.

The sources of the information contained herein are considered reliable by China Renaissance Capital. However, China Renaissance Capital makes no representation or warranty as to the accuracy, completeness, or timeliness of the information contained herein. The opinions, analyses, forecasts, projections, and expectations set forth herein are current only as of the date of publication and are subject to change without prior notice. China Renaissance Capital may have or seek business relationships with the companies mentioned herein; therefore, recipients should be aware that potential conflicts of interest may exist that could affect the objectivity of this document. China Renaissance Capital shall not be liable for any direct or indirect losses arising from the use of this document. This document is protected by copyright and other intellectual property rights.